The 2026 EU Immuno-Oncology Drug Development Summit will educate and engage the European IO community on the next wave of IO therapeutics and ensure that active, innovative, new therapies are rapidly and appropriately moved into clinical testing.
The program will be a key forum for continuing exploration and discussion of best practices for modern IO drug development, including study design, regulatory pathways and emerging technologies.